Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
Skip to main content
Home
e-Protocol
The OCREVUS SC e-Protocol provides an administration and storage protocol that outlines:
- The storage, and safety protocols for OCREVUS SC.
- Detailed information about the preparation and administration of the OCREVUS SC injection, including dosage, pre-medications, injection sites, and post-administration monitoring.
- Safety information, contraindications, potential adverse reactions, special warnings and precautions for use.
- Up to date fertility, pregnancy, and lactation considerations.
Please download the material here
References:
- OCREVUS IV Summary of Product Characteristics
2. OCREVUS SC Summary of Product Characteristics
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.
